PharmaSGP Holding Past Earnings Performance
Past criteria checks 4/6
PharmaSGP Holding has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 20.8% per year. PharmaSGP Holding's return on equity is 55.9%, and it has net margins of 16.6%.
Key information
3.4%
Earnings growth rate
3.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 20.8% |
| Return on equity | 55.9% |
| Net Margin | 16.6% |
| Next Earnings Update | 28 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How PharmaSGP Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 110 | 18 | 56 | 0 |
| 31 Mar 24 | 107 | 18 | 54 | 0 |
| 31 Dec 23 | 101 | 16 | 51 | 0 |
| 30 Sep 23 | 98 | 15 | 51 | 0 |
| 30 Jun 23 | 94 | 14 | 48 | 0 |
| 31 Mar 23 | 89 | 13 | 46 | 0 |
| 31 Dec 22 | 86 | 12 | 44 | 0 |
| 30 Sep 22 | 83 | 11 | 64 | 0 |
| 30 Jun 22 | 81 | 11 | 42 | 0 |
| 31 Mar 22 | 74 | 11 | 46 | 0 |
| 31 Dec 21 | 65 | 11 | 36 | 0 |
| 30 Sep 21 | 61 | 8 | 36 | 0 |
| 30 Jun 21 | 56 | 8 | 34 | 0 |
| 31 Mar 21 | 59 | 9 | 36 | 0 |
| 31 Dec 20 | 63 | 11 | 35 | 0 |
| 30 Sep 20 | 65 | 16 | 31 | 0 |
| 30 Jun 20 | 65 | 17 | 31 | 0 |
| 31 Mar 20 | 64 | 17 | 22 | 0 |
| 31 Dec 19 | 63 | 17 | 30 | 0 |
| 31 Dec 18 | 61 | 15 | 29 | 0 |
| 31 Dec 17 | 53 | 12 | 28 | 0 |
Quality Earnings: PSG has high quality earnings.
Growing Profit Margin: PSG's current net profit margins (16.6%) are higher than last year (15.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PSG's earnings have grown by 3.4% per year over the past 5 years.
Accelerating Growth: PSG's earnings growth over the past year (28.7%) exceeds its 5-year average (3.4% per year).
Earnings vs Industry: PSG earnings growth over the past year (28.7%) did not outperform the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: Whilst PSG's Return on Equity (55.85%) is outstanding, this metric is skewed due to their high level of debt.